Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial-Reference-Cited by-同舟云学术

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Feng Guang-Wei¹,Wang Zhong-Fang²³,He Peng⁴,Lan Qin-Ying⁵,Ni Ling⁶,Yang Ya-Zheng⁶,Wang Chen-Fei⁴,Cui Ting-Ting²,Huang Li-Li¹,Yan Yong-Qiang⁷,Jiang Zhi-Wei⁸,Yang Qing⁵,Yu Bang-Wei⁵,Han Xi⁵,Chen Jing-Jing⁹,Yang Shu-Yuan⁹,Yuan Lin⁹,Zhou Ling-Yun⁵,Liu Ge⁵,Li Ke⁵,Huang Zhen⁹,Zhao Jin-Cun²³,Hu Zhong-Yu⁴,Xie Zhi-Qiang¹

Affiliation:

1. Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China

2. State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China

3. Division of Drug and Vaccine Research, Guangzhou Laboratory, Bioland, Guangzhou, GD, China

4. Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China

5. R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China

6. School of Medicine, Tsinghua University, Beijing, China

7. Vaccine Program Office, Xiangcheng County Center for Disease Control and Prevention, Xiangcheng, HA, China

8. Statistics and Decision Sicence, Beijing Key Tech Statistical Consulting Co. Ltd, Beijing, China

9. R&D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China

Funder

Coalition for Epidemic Preparedness Innovations

Joint Construction Project of Henan Provincial Medical Science and Technology Research Plan in 2021

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2262635

Reference20 articles.

1. Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion

2. SARS-CoV-2 Vaccine Development: Current Status

3. Recombinant vaccines for COVID-19

4. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants

5. GSK. Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine; [accessed 2022 Aug 29]. https://www.gsk.com/en-gb/media/press-releases/sanofi-gsk-first-to-report.